Support our Foundation of Myology project
1655 news items
The Institute is recruiting a Research Associate and an Engineer (M/F)
On 07/05/2021
A research associate and an engineer positions are available in the BOND group, at the Myology Center for Research, Sorbonne University, INSERM U974, Institute of…
The phenotype distinction between Myoshi distal myopathy and LGMD R2 is no longer justifiable in dysferlinopathy
On 07/05/2021
Dysferlinopathy encompasses several clinical entities, having in common a deficit in dysferlin, a protein involved in muscle fibre membrane repair mechanisms. Initially reduced simply to…
New study supports leuprorelin in Kennedy disease
On 04/05/2021
Kennedy’s disease is a relatively slow-growing motor neuron disease. Among the various clinical signs, swallowing disorders strongly affect the quality of life of patients. Leuprorelin,…
At AAN Congress, nipocalimab demonstrates efficacy and good tolerance in generalized myasthenia gravis
On 03/05/2021
Neonatal Fc receptors (FcRn) prevent the degradation of immunoglobulins G (IgG), promoting their recycling. Nipocalimab is a monoclonal antibody directed against FcRn giving hope for…
Nutritional ketosis before exercise shows benefits in type III glycogenosis with major muscle damage
On 29/04/2021
Cori-Forbes disease or type III glycogenosis is an inherited disease caused by a deficiency of the debranching enzyme, causing a defect in the production of…
A new functional scale adapted to LGMD, in particular to dysferlinopathies
On 29/04/2021
Functional scales are very useful in neuromuscular diseases (NMD), for monitoring NMD patients as well as in therapeutic trials where they can be used as…
Oculopharyngodistal myopathy: already 3 genes identified
On 22/04/2021
Oculopharyngodistal myopathy (OPDM) and oculopharyngeal muscular dystrophy (OPMD) are due to a a repeat expansion of triplets. OPDM is much rarer than DMOP and…
DMD: gene therapy clinical trial starting in France
On 21/04/2021
A first patient with Duchenne muscular dystrophy has received a gene therapy treatment at I-Motion, the paediatric clinical platform for neuromuscular diseases, in the context…
Life expectancy is increasing for DMD thanks to the angiotensin-converting enzyme (ACE) inhibitors
On 12/04/2021
In Duchenne muscular dystrophy (DMD), heart involvement leads to heart failure. Angiotensin-converting enzyme (ACE) inhibitors are routinely prescribed at around 10 years of age for…
Identification of a slow and gradual decline in muscle strength in GNE myopathy and tailored tools to evaluate it
On 06/04/2021
Characterised by distal muscle weakness, GNE myopathy (also known as Nonaka myopathy, hereditary inclusion body myositis, distal myopathy with rimmed vacuoles or quadriceps-sparing myopathy) is…
What is the purpose of the exon 31 in the modelling of clathrin structures in muscle cells? – Interview with S. Vassilopoulos
On 17/07/2020
Interview with Stéphane Vassilopoulos, researcher at the Muscle Organization & Therapy of Dominant Centronuclear Myopathy laboratory in Team 2 at the Institute of Myology Research…
Preliminary results of FIREFISH, a trial evaluating ridisplam in type 1 SMA
On 11/05/2020
The primary endpoint of the second part of the FIREFISH clinical trial has been met. This is an announcement by Roche and PTC Therapeutics, the…
Drug-induced myopathies: beware of the toxic effects of immune control point inhibitors
On 03/03/2020
Drug-induced myopathy is among the most common causes of muscle disease. An association has recently been described between programmed death-1 (PD-1)/PD-1 ligand (PD-L1) inhibitors and…
Release of the 77th newsletter from the Institute
On 31/01/2020
The Institute of Myology wishes you all the best for 2020 Welcome to the first issue of our newsletter for the new year! …
Expanding the phenotype of filamin-C-related myofibrillar myopathy
On 07/05/2019
A tean of Danish researhers reports three patients with a rare filamin C myofibrillar myopathy. They present with atypical symptoms that expand the phenotype of…